INTRODUCTION
Cholangiocarcinoma (CCA) is a hepatobiliary cancer that displays features of bile ductular diff erentiation. Th e overall incidence of CCA has been on the rise. Th ese tumors are highly lethal, as the 5-year survival rate has remained low at approximately 10% since the 1980s ( 1 ) . CCA is currently classifi ed on the basis of anatomic location into three distinct subsets: intrahepatic, perihilar, and distal CCA ( 2, 3 ) . Th ese subsets are diff erent in their genetics, clinical presentation, management, and patient outcomes. Each subset therefore requires its own staging system for predicting survival.
are limited, and the current practice standard is chemotherapy with gemcitabine plus cisplatin. However, this systemic chemotherapeutic approach is only palliative, and median life expectancy is extended a mere 3 months ( 7 ) . Novel therapies for pCCA are therefore urgently needed. Th e design of clinical trials for pCCA is hampered by the lack of a nonoperative clinical staging system for pCCA. Such a staging system is needed to appropriately stratify patients within clinical trial designs.
Currently, there are three commonly used pCCA classifi cation systems: the Bismuth-Corlette classifi cation, the Memorial SloanKettering Cancer Center staging system, and the American Joint Committee on Cancer/Union for International Cancer Control tumor-node-metastasis (TNM) system (8) (9) (10) . All of these are operative staging systems; thus, none can be used to predict survival of patients with unresectable disease. Th e Bismuth-Corlette classifi cation and the Memorial Sloan-Kettering Cancer Center staging system are primarily used for guiding surgical approach in patients who are eligible for surgical resection. Th e TNM staging system is specifi cally designated for predicting prognosis; however, it is based solely on information from resected specimens, and therefore it is not applicable to most pCCA patients who have unresectable disease and must be staged on clinical, rather than pathologic, criteria ( 10 ) .
Because none of the current staging systems are relevant to the entire cohort of pCCA patients, a broader staging system based on nonoperative information is required for prognostication in clinical practice and for adequate stratifi cation of patients in clinical trials of novel therapies ( 11, 12 ) . To address this defi ciency, we constructed a new staging system based on independent predictors of survival at the time of pCCA diagnosis and assessed the ability of the new staging system to predict survival in a large cohort of pCCA patients seen at a single referral center.
METHODS

Patients and procedures
Th e study was approved by the Mayo Clinic Institutional Review Board. All patients diagnosed with pCCA seen at Mayo Clinic, Rochester, MN between January 1, 2002 and December 31, 2010 were identifi ed ( n =524). We searched for pCCA cases in the Mayo Clinic Life Sciences System using the ICD-9-CM code of "156.1" and/or the keywords "cholangiocarcinoma" and "bile duct cancer" to identify all potential pCCA patients. We then reviewed the medical record. Patients who received any treatments for pCCA before their initial Mayo visit, except for biliary stenting, e.g., surgical resection or exploration ( n =54), or chemotherapy ( n =24), those who did not have radiologic imaging available for review ( n =25), and those who did not provide authorization for research ( n =8) were excluded. Th e diagnosis of CCA was established by any of the following six criteria: (i) surgical histopathology from resected tumor or residual tumor in the explanted liver ( n =102); (ii) histology from intraluminal endoscopic core biopsy, percutaneous needle biopsy, or intraoperative biopsy ( n =105); (iii) intraluminal brush cytology (111 positive cytology and 12 suspicious cytology; suspicious cytology at Mayo has a specifi city of >95% for the diagnosis of CCA in the absence of primary sclerosing cholangitis (PSC)) (13) (14) (15) , (iv) polysomy demonstrated by fl uorescence in situ hybridization of intraluminal brush cytology specimens in combination with a malignant-appearing biliary tract stricture demonstrated by radiologic imaging or a mass lesion on cross-sectional imaging studies ( n =23) ( 3, 16, 17 ) , (v) a CA-19-9 level >100 U/ml in the setting of a malignant-appearing biliary tract stricture demonstrated by radiologic imaging and without bacterial cholangitis ( n =43) ( 3, 13, 18 ) , or (vi) a perihilar mass lesion with a malignant-appearing biliary tract stricture on cross-sectional imaging studies with evidence of malignant clinical progression during the follow-up period ( n =17, the median follow-up period was 9.3 months).
Baseline characteristics, including Eastern Cooperative Oncology Group (ECOG) performance status defi ned on the basis of patient report of the level of activity and symptoms, CA 19-9 level, and radiographic fi ndings at the time of diagnosis were retrospectively abstracted. Tumor extent, vascular encasement (defi ned as tumor soft tissue partially or completely surrounding a vessel), lymph node metastasis, and metastatic spread to liver (indicating intrahepatic metastasis) or peritoneum (or other organs) at the time of pCCA diagnosis, before any operative procedures, were ascertained on the basis of the hepatobiliary radiologist report in the medical record (computerized tomography scan and/or magnetic resonance imaging). Tumor size was determined by the maximum radial diameter of the largest tumor.
In the diagnostic and treatment algorithm for pCCA at Mayo Clinic, all patients were evaluated for resectibility, and if deemed ineligible, liver transplantation was considered. Patients who were not candidates for either surgical resection or transplantation were considered for systemic chemotherapy or best supportive care. Palliative biliary drainage with biliary tract stenting (either endoscopic or percutaneous) was performed to relieve cholestasis in patients with jaundice. Patients with potentially resectable disease underwent chest imaging (X-ray and/or computerized tomography scan) to rule out lung metastases. Th ose patients with either unresectable pCCA or pCCA arising in the setting of PSC who were potentially eligible for liver transplantation underwent endoscopic ultrasound as part of the pretransplant evaluation protocol, to assess for regional lymph node involvement.
Statistical analysis
Data analysis was performed using SAS 9.1 (SAS Institute, Cary, NC). Baseline characteristics were summarized as frequency (cate gorical variables) and mean±s.d. or median (range) as appropriate (continuous variables). Death was the primary end point. Median survival, defi ned as time from the fi rst visit date at Mayo Clinic to the last follow-up or death date, was estimated using the Kaplan-Meier method. For the main analysis, all patients were followed up from treatment assignment to death, ignoring any treatment changes, with the primary goal of assessing the patients' overall survival. We also performed a second analysis of patients receiving liver transplantation by treating transplant and death as competing risks in order to better understand their trajectories. Follow-up was censored on May 31, 2013 . Th e median follow up of the entire cohort was 78.2 months.
LIVER
Staging System for Perihilar Cholangiocarcinoma
A total of 413 pCCA patients were included in the analysis ( Supplementary Figure S1 online). Patients were categorized into four groups on the basis of initial intended treatment as follows: (i) transplant group including patients listed for the protocol of neoadjuvant chemoradiation, followed by liver transplantation (i.e., including both intended and actual transplantation); (ii) resection group including those who underwent resection with curative intent (i.e., including both aborted and completed resection); (iii) palliative biliary drainage group including those who received stenting in combination with nonsurgical therapies, e.g., systemic chemotherapy, and (iv) best supportive care (BSC) group. Th ere were 92, 82, 224, and 15 patients in the transplant, resection, palliative biliary drainage, and BSC groups, respectively ( Supplementary Figure S1 ) .
To identify predictors of survival at the time of pCCA diagnosis, hazard ratios (HRs) and 95% confi dence intervals (95% CIs) were calculated using Cox proportional hazards regression analysis. Th e treatment type was included as both an ordinary covariate and as a stratifi cation factor, to verify that the results were robust to the manner of inclusion. Th e fi rst model included the targeted treatment group as a covariate, because that is one of the strongest predictors of later survival. Th e second model included the treatment group as a stratifi cation factor. When stratifying on treatment, other covariates in the risk model examined the risk of each subject relative to others in the same treatment strata. For the continuous variable tumor size, we fi rst assessed the overall shape of the relationship between tumor size and survival of patients using a smoothing spline function-e.g., does risk increase linearly or have a threshold?-and used the observed pattern to guide its inclusion in the fi nal model. Owing to the large sample size, we were able to test all of the predictors in both a univariate and a multivariate model. P <0.05 was considered signifi cant.
Signifi cant variables identifi ed by the multivariate analyses were incorporated into a four-level staging system. We also included three a priori candidate predictors proposed in our previous publication, i.e., multicentric tumors (indicating intrahepatic metastasis), vascular encasement, and lymph node metastasis, as they are major determinants of surgical resectability and eligibility for liver transplantation ( 3, 12 ) . Patients were categorized on the basis of this staging system, and survival was compared using the log-rank test.
Th e predictive performance of the proposed staging system was examined along with the current 7th TNM staging system using the concordance score. It is important to note that the patients in our cohort were categorized by TNM stage on the basis of radiologic fi ndings instead of the surgical pathologic fi ndings required for the bona fi de TNM stage. Because pathologic information on tumor depth (T1) and extension of tumor into the surrounding tissues (T2) was not available in 75% of our cohort, stages I (T1N0M0) and II (T2N0M0) were grouped together. Table 1 displays demographic, clinical, and tumor characteristics. A total of 113 (27%) patients had PSC (of whom 17 had clinical features of portal hypertension, as assessed by ascites, jaundice, and esophageal varices) and 9 (2%) had non-PSC-related cirrhosis as their underlying risk factors.
RESULTS
Baseline characteristics
Survival predictors of pCCA patients
As expected, initial intended treatment type was independently associated with survival ( Supplementary Table S1 ). To assess the impact of potential nonproportional hazards on the treatment arm, treatment type was treated as strata in the model determining the impact of other variables on survival ( Supplementary  Table S2 ). Of the variables assessed at the time of diagnosis, age, ECOG status, tumor size, peritoneal (or other organ) metastasis diagnosed by either biopsy or imaging, and CA 19-9 were independently associated with survival, suggesting that these variables have an impact on survival aft er accounting for treatment modality ( Supplementary Table S2 ). Diff erent cutoff s of CA 19-9, i.e., ≥100, ≥500, and ≥1,000 U/ml, were further examined to identify the optimum cutoff that best discriminated survival outcomes. We found that the median survivals were 27.4, 13.3, 12.9, and 5.9 months, with HRs (95% CI) of 1 (reference), 1.8 (1.3-2.5), 2.1 (1.3-3.3), and 4.8 (3.5-6.7) for patients with CA 19-9 <100, 100-499, 500-999, and ≥1,000 U/ml, respectively. Th e CA 19-9 cutoff of ≥1,000 U/ml was therefore chosen for the multivariate analysis. Th e adjusted HR (95% CI) was 1.2 (1.1-1.4) for age per 10 years; 1.6 (1.2-2.1) for ECOG 1 or 2 and 10.6 (5.1-22.00) for ECOG 3 or 4 when compared with ECOG 0; 1.2 (1.1-1.4) for tumor size; 3.0 (1.8-4.9) for peritoneal metastasis; and 1.8 (1.3-2.5) for CA 19-9≥1,000 U/ml, P =0.0037, 0.0012, <0.0001, 0.0029, <0.0001, and 0.0002, respectively. Interestingly, tumor number, vascular encasement, and lymph node metastasis were not statistically signifi cant in the treatment strata model, suggesting that the impact of these variables on survival may be diff erent among the treatment groups.
Because ECOG status, tumor size, peritoneal metastasis, and CA 19-9≥1,000 U/ml were independently associated with survival, they were included in the proposed staging system. We selected a tumor size cutoff of 3 cm for two reasons: fi rst, the median tumor size was 3 cm for the entire cohort, and having a tumor size greater than 3 cm was associated with a HR (95% CI) of death of 2.8 (2.2-3.6), P <0.0001. Th e median survival was 18.2 vs. 5.3 months for those with tumor size ≤3 cm vs. >3 cm, respectively. Second, it was shown that the 5-year survival aft er liver transplantation was more than 80% for pCCA patients who had tumor size <3 cm, and a tumor size cutoff of a radial diameter of 3 cm has been established as the optimal cutoff for patient selection for liver transplantation for pCCA ( 6, 18 ) . Table 2 summarizes the proposed staging system based on independent and a priori candidate variables. Figure 1 shows the staging algorithm. On the basis of this algorithm, 76, 101, 164, and 58 patients were classified as stages I, II, III, and IV, respectively (14 patients could not be classified owing to the lack of information on ECOG status ( n =1) or CA 19-9 ( n =13)). 
Proposed pCCA staging system
Survival of pCCA patients classifi ed by the proposed staging system
At the time the data were censored, 281 (70%) of 399 patients classifi ed by the proposed staging algorithm had died. Th e median survival of the entire cohort was 12.2 months, with 1-and 5-year survival rates of 51% and 18%, respectively.
Survival of pCCA patients was clearly distinguished by the proposed four stages ( Figure 2a ) . Th e median survivals of stages I, II, III, and IV patients were 48.6, 21.8, 8.6, and 2.8 months, with HRs (95% CI) of 1.0 (reference), 1.8 (1.2-2.7), 5.1 (3.5-7.5), and 16.6 (10.5-26.2), respectively (overall P <0.0001; Table 3 ). Aft er adjusting for treatment using the treatment strata model, the HRs of stages I, II, III, and IV were 1.0 (reference), 1.7 (1.2-2.6), 3.1 (2.0-4.6), and 8.7 (5.2-14.6), respectively ( P <0.0001).
Survival of pCCA patients receiving different treatments
Th e median survival of pCCA patients was signifi cantly diff erent among treatment groups, i.e., 60.2, 25.3, 5.8, and 5.6 months Figure 2d ; Supplementary Table S5 ). Reasons for the selection of stenting alone for patients with early-stage disease, i.e. stage I, included technical reasons which made surgery not feasible ( n =6), comorbid diseases ( n =3), and other patient factors ( n =2).
In the BSC group, 1, 10, and 4 patients were classifi ed as stage II, III, and IV, respectively. Th e median survivals of stage III and stage IV patients were 6.1 and 1.0 months, respectively ( P =0.02; Supplementary Table S6 ).
Predictive performance of the proposed staging system vs. the TNM staging system Figure 2a shows survival of patients classifi ed by the TNM staging system using radiologic information. Th e median survivals of for the transplant, resection, palliative biliary drainage, and BSC groups, respectively ( P <0.0001). When transplantation and death were treated as competing risks (i.e., to estimate survival of patients who received complete transplantation), the patients did not reach median survival with 1-and 5-year survival of 96% and 91%, respectively. Survival of patients in the palliative biliary drainage group was not statistically diff erent from that of patients in the BSC group ( P =0.17).
Survival of pCCA patients in each treatment group classifi ed by the proposed staging system
Survival for patients within each treatment group was discriminated by the proposed stages (3-month, 6-month, 1-year, and 5-year Kaplan-Meier estimates, and HRs (95% CI) are shown in Supplementary Tables S3-6 ). Of the 92 patients in the transplant group, 33, 40, and 19 were classifi ed as stage I, II, and III, respectively. Stage I patients did not reach median survival, whereas stage II and stage III patients had median survivals of 52.1 and 15.5 months, respectively ( P <0.0001; Figure 2b ; Supplementary  Table S3 ) .
Of the 82 patients in the resection group, 32, 26, and 16 patients were classifi ed as stage I, II, and III, respectively; 8 patients had missing CA 19-9 values for staging. Although the overall median survivals of stages I, II, and III patients in the resection group were not statistically diff erent, i.e., 35.2, 20.2, and 9.7 months, respectively ( P =0.41; Figure 2c ), stage I patients had a better 2-year survival rate than stage II and stage III patients, i.e., 68%, 44%, and 33%, respectively ( P =0.41; Supplementary Table S4 ).
Of the 224 patients in the palliative biliary drainage group, 11, 34, 119, and 54 were classifi ed as stage I, II, III, and IV, respectively; 6 had missing CA 19-9 values for staging. Th e median survivals were 20.8, 12.4, 7.7, and 3.0 months, respectively ( P <0.0001; The entire cohort 
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DISCUSSION
Th e main limitation of currently available classifi cations of pCCA is that they are not applicable to the entire cohort of pCCA patients seen in the clinic. Th e Bismuth-Corlette classifi cation, cance, the HRs of the TNM stages were close to each other, suggesting that the discriminative power of the TNM staging system was low. When patients were categorized by treatment, the TNM stages were associated with survival of patients only in the transplant group ( P =0.004) but not in the other groups ( P >0.05; Figure 2b-d ;  Supplementary Tables S7-10 ). Further, the median survivals of TNM I/II, III, and IV patients in the transplant group did not decrease in order as anticipated, instead, they were median survival not reached, 15.5, and 31.1 months, with HRs (95% CI) of 1.0 (reference), 4.1 (1.2-14.4), and 2.8 (1.5-5.5), respectively (overall P =0.004).
To assess the performance of the staging systems, we estimated the concordance scores of both staging systems. Th e concordance score (standard error) of the proposed staging system, 0.725 (0.018), was better associated with the outcome of patient death than that of the TNM staging system: 0.614 (0.017). When patients were categorized by treatments, the concordance score of the proposed staging system was higher than that of the radiologic TNM staging system for all treatment types ( Table 5 ) . including tumor location and extent, was designed to guide surgical treatment ( 8 ) . It is not designed as a staging system and does not relate to survival (20) (21) (22) . Th e Memorial Sloan-Kettering Cancer Center (MSKCC) staging system, including tumor location and extent classifi ed by the Bismuth-Corlette classifi cation, vascular involvement, and lobar atrophy, is a preoperative staging system that has been mainly used to determine potential surgical resectability ( 9 ) . Th e MKSCC system was developed using a cohort of 225 patients with both unresectable and resectable disease. Although it was originally shown to predict survival of pCCA patients, this fi nding was not replicated in other studies ( 23, 24 ) . Th e patient cohort had an ascertainment bias toward surgically resectable patients, as 71% of the cohort underwent surgery with curative intent and only 29% presented with unresectable disease. Th e main utility of the MKSCC system therefore remains for defi ning surgical resectability. In addition, when the MKSCC system was developed, liver transplantation was not an established treatment modality for pCCA. Th e TNM staging system is the only pCCA classifi cation that is specifi cally developed for predicting survival ( 10 ) . It was updated in 2010 and shown to have better predictive performance than the prior version ( 25 ) ; however, other studies reported that the current TNM staging system was not associated with the overall survival of pCCA patients undergoing surgical resection ( 24, 26 ) . Recently, a new staging system for pCCA has been proposed, which includes consideration of the severity of underlying liver disease and detailed information on tumor extent and vascular involvement, but again it relies on fi ndings from surgical pathology, and its correlation with survival has not been examined ( 27 ) .
On the basis of analysis of 413 pCCA patients, we have developed a staging system for pCCA, which provides patient homogeneity in terms of survival. Th e staging system takes into account both patient and tumor characteristics, including ECOG status, tumor size and number, vascular encasement, presence and location of metastases, and CA 19-9 level. Th e staging system, developed using nonpathologic information, has excellent discriminatory power to predict survival of patients in each stage and had better prognostic performance, demonstrated by the higher concordance score, than the current TNM staging system. Th e major advantage of our proposed staging system over the current staging systems is that our system can provide prognostication and stratify both surgical and nonsurgical patients. All variables in our system are obtained preoperatively at the time of diagnosis and are therefore relevant to all pCCA patients, not only those eligible for surgery. All variables are easily obtained, as they are components of the routine clinical evaluation of patients with suspected pCCA. Th e new staging system includes cases from the more recent era of liver transplantation for pCCA, and it also allows prognostication for patients with advanced disease. It therefore covers the full breadth of presentation of pCCA patients.
As expected, age, ECOG status, tumor size, peritoneal metastasis, and CA 19-9 levels were independent predictors of survival in the current study. ECOG status 3-4 was the strongest predictor of survival, followed by peritoneal metastasis. Interestingly, we found that CA 19-9 was an independent predictor of survival. Although CA 19-9 has been widely used as a diagnostic marker for CCA, whether it can be used as a biomarker for predicting survival has not been well studied. A CA 19-9 of >100 U/ml was shown to be a predictor for recurrence in a subgroup of pCCA patients treated with liver transplantation ( 13 ) . In this study, CA 19-9 ≥1,000 U/ml was signifi cantly associated with worse survival regardless of stage or treatment received. Although a number of biomarkers were recently shown to be associated with prognosis of pCCA patients, these biomarkers remain in phase 1 or 2 studies of cancer biomarker development, i.e., most biomarkers were obtained from surgical specimens, the studies were conducted in a small cohort, mainly in patients undergoing surgery, no validation studies are available, and no comparisons of the predictive performance with the CA 19-9 have been made (28) (29) (30) (31) (32) (33) (34) .
Although tumor number, vascular encasement, and lymph node metastasis have been shown to predict pCCA survival in previous studies (20) (21) (22) 24, (35) (36) (37) , we did not fi nd independent associations between these variables and survival, likely owing to correlations between individual tumor characteristics, for example, tumor size and number (data not shown).
Th ere are a number of strengths of our study. Mayo Clinic is a national and international referral center for patients with PSC and/or CCA. As such, we have a large cohort of pCCA patients presenting with all disease stages. Th e follow-up duration was long enough to have an adequate number of patients with the outcome of interest (i.e., death), allowing us to generate statistically robust models predicting mortality. Importantly, including treatments as strata is the more robust choice for analysis. In this data set, however, the coeffi cients for all of the other variables in the model including treatment as covariate (data not shown) hardly changed with the treatment strata model, indicating the robustness of our analyses. Th e patients are well distributed among the proposed stages, i.e., 19, 25, 41, and 15%, and likely refl ect the proportions of pCCA patients typically seen in practice.
Th ere are several limitations to the study. Th e staging system was developed using a cohort of patients seen in a single center, albeit referred from throughout North America, where the specialized treatment modalities, including liver transplantation, for pCCA are available. External validation of the new proposed staging system in an independent cohort is required to determine whether the proposed staging system can be generalized to other institutions. However, owing to the relatively small number of patients with pCCA seen at even high volume hepatobiliary cancer centers, we were not able to include a validation cohort in the present study. We are initiating an eff ort to validate the proposed staging system in a multicenter cohort of pCCA patients of whom a reasonable proportion has been treated with liver transplantation. Because there is no standard clinical staging system for pCCA currently available for us to determine whether the proposed staging system is superior to the current standard clinical staging system, the radiologic TNM staging system was used instead of the classical pathologic TNM staging as the gold standard for comparison, in order to allow us to include all patients in the comparison analysis. We did attempt to compare the performance of the proposed staging system to that of the classical TNM staging system in patients undergoing resection. However, the number of patients treated with resection was too small to draw any conclusions. Another limitation was that this staging system was developed from a Western population, in which PSC is a major risk factor for CCA. Whether this staging system is applicable to other populations with diff erent ethnic backgrounds and risk factors is unknown.
In summary, a major benefi t of this proposed staging system is that it can be applied to all pCCA patients regardless of the treatment received, and it will permit the reliable stratifi cation of patients for phase 2 and 3 clinical trials into more homogeneous cohorts with similar expected survival outcomes.
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